M&A Deal Summary

Agenus Acquires 4-Antibody AG

On February 13, 2014, Agenus acquired life science company 4-Antibody AG for 40M USD

Acquisition Highlights
  • This is Agenus’ 1st transaction in the Life Science sector.
  • This is Agenus’ largest (disclosed) transaction.
  • This is Agenus’ 1st transaction in Switzerland.

M&A Deal Summary
Date 2014-02-13
Target 4-Antibody AG
Sector Life Science
Buyer(s) Agenus
Deal Type Add-on Acquisition
Deal Value 40M USD
Advisor(s) Torreya Partners LLC (Financial)

Target

4-Antibody AG

Basel, Switzerland
4-Antibody AG, a private European-based biopharmaceutical company.

Search 200,197 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Agenus

Lexington, Massachusetts, United States
Category Company
Founded 1994
Sector Life Science
Employees389
Revenue 156M USD (2023)
DESCRIPTION

Agenus is a biotechnology company developing treatments for cancers and infectious diseases. Agenus was incorporated in 1994 and is based in Lexington, Massachusetts.

DEAL STATS #
Overall 1 of 3
Sector (Life Science) 1 of 3
Type (Add-on Acquisition) 1 of 2
Country (Switzerland) 1 of 1
Year (2014) 1 of 1
Size (of disclosed) 1 of 2
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-04-08 Celexion - Key Antibody Assets

Cambridge, Massachusetts, United States

Celexion's Key Antibody Assets is a SECANT yeast display platform for the generation of novel monoclonal antibodies. SECANT is designed to enable highly efficient interrogation of drug targets such as checkpoint proteins.

Buy $4M
Mergr

Product

Company

Legal